A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Trial Profile

A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms NIVOREN
  • Sponsors UNICANCER
  • Most Recent Events

    • 06 Jun 2017 Preliminary results (n=588, data cut off: Dec 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 18 Feb 2017 Results (n=45,data cut off Jul 2016) assessing first tumor growth assessment presented at the 2017 Genitourinary Cancers Symposium.
    • 18 Feb 2017 Results (n=62) assessing brain metastases from metastatic renal cell carcinoma patients treated with nivolumab at Gustave Roussy, presented at the 2017 Genitourinary Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top